Jazz Pharmaceuticals (JAZZ)
(Real Time Quote from BATS)
$109.33 USD
-2.72 (-2.43%)
Updated Jun 10, 2024 11:06 AM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Jazz Pharmaceuticals PLC [JAZZ]
Reports for Purchase
Showing records 41 - 60 ( 249 total )
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Solid Top Line and Big Cost Cuts Leave Plenty of Flexibility for R&D Investment and M&A; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Jazz Bolstering Oncology Pipeline With Risk-Mitigated Deal for Zanidatamab in HER2+ Cancers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
2Q Thorough Beat; Even Bigger Than Reported vs. Applesto- Apples Street Numbers; Reiterate Buy; Tweak PT to $204
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
1Q Miss, But Operating Leverage Flex Should Confer Earnings Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Another Big Beat; Strong Xywav Start in IH; First-Time Guidance Sets Tone for Outperformance in 2022; Raise PT to $215
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
3Q21: Post-GW Leverage Flexed; Updated 2021 Rev Guidance In Line with Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O